ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
3 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
531
|
178K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
4 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
531
|
178K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
3 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
531
|
178K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
4 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
531
|
178K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
47 |
10K |
1 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
47
|
10K
|
1
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
47 |
10K |
2 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
47
|
10K
|
2
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
47 |
10K |
4 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
47
|
10K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
47 |
10K |
4 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
47
|
10K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
47 |
10K |
1 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
47
|
10K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
ma420
|
41 |
13K |
29 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
41
|
13K
|
29
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
47 |
10K |
0 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
47
|
10K
|
0
|
|
ASX - By Stock
|
SIS |
Re:
Ann: Annual General Meeting Address and Presentation
|
|
ma420
|
22 |
5.1K |
1 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
22
|
5.1K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
21 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
213
|
89K
|
21
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
19 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
213
|
89K
|
19
|
|
ASX - By Stock
|
COV |
Cleo - Research & Valuation
|
|
ma420
|
2 |
765 |
3 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
2
|
765
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
3 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
624
|
199K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
0 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
624
|
199K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAAO HOLDERS AS AT 31/05/24
|
|
ma420
|
24 |
6.0K |
4 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
24
|
6.0K
|
4
|
|
ASX - By Stock
|
PAA |
Pharmaust - Media & News
|
|
ma420
|
41 |
13K |
31 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
41
|
13K
|
31
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
2 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
624
|
199K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
2 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
624
|
199K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
4 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
624
|
199K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
7 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
230
|
103K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
18 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
213
|
89K
|
18
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
1 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
213
|
89K
|
1
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
1 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
3 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
55
|
17K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity strengthens Cu-64 network with new supply agreement
|
|
ma420
|
50 |
15K |
7 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
50
|
15K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity strengthens Cu-64 network with new supply agreement
|
|
ma420
|
50 |
15K |
7 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
50
|
15K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity strengthens Cu-64 network with new supply agreement
|
|
ma420
|
50 |
15K |
2 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
50
|
15K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity strengthens Cu-64 network with new supply agreement
|
|
ma420
|
50 |
15K |
16 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
50
|
15K
|
16
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity strengthens Cu-64 network with new supply agreement
|
|
ma420
|
50 |
15K |
11 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
50
|
15K
|
11
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
17 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
213
|
89K
|
17
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Pause in Trading
|
|
ma420
|
41 |
7.8K |
1 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
41
|
7.8K
|
1
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
ma420
|
37 |
9.5K |
0 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
37
|
9.5K
|
0
|
|
ASX - By Stock
|
COV |
Cleo - General discussion
|
|
ma420
|
2 |
918 |
1 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
2
|
918
|
1
|
|
ASX - By Stock
|
COV |
Cleo Media Thread
|
|
ma420
|
0 |
244 |
2 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
0
|
244
|
2
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
0 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
4 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
55
|
17K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
9 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
531
|
178K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
5 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
531
|
178K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
2 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
531
|
178K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
1 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
531
|
178K
|
1
|
|